Franzese O, Graziani G. Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints. Cancers (Basel) 2022;14. [PMID: 36428727 DOI: 10.3390/cancers14225633][Reference Citation Analysis]
2
Liao M, Beltman J, Giordano H, Harding TC, Maloney L, Simmons AD, Xiao JJ. Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib. Clin Pharmacokinet 2022;61:1477-93. [PMID: 36107395 DOI: 10.1007/s40262-022-01157-8][Reference Citation Analysis]